Is first eye cataract surgery cost effective?

Article

First eye cataract surgery is probably more cost-effective over a patient's remaining lifetime than if they have no surgery at all.

First eye cataract surgery is probably more cost-effective over a patient's remaining lifetime than if they have no surgery at all, according to a study published in the December issue of the British Journal of Ophthalmology.

Tracey Sach and colleagues from the University of East Anglia, UK evaluated the cost-effectiveness of first eye cataract surgery compared with no surgery from a health service and personal social services perspective. A sample of 306 women aged 70 years or older with bilateral cataracts were randomized to cataract surgery (expedited) or control (routine 12-month wait for surgery).

The operated group cost a mean £2,004 (approx. €2,800) more than the control group over one year. However, they experienced an average 0.456 fewer falls, an incremental cost per fall prevented of £4,390 (approx. €6,150). The mean gain in quality of life years (QALYs) per patient was 0.056. The incremental cost-utility ratio was £35,704 (approx. €50,000), above the currently accepted UK threshold level of willingness to pay per QALY of £30,000 (approx. €42,000). However, in an analysis modelling costs and benefits over a patients' expected lifetime, the incremental cost per QALY was £13,172 (approx. €18,500) under conservative assumptions.

According to the researchers, although first eye cataract surgery was not cost-effective over the trial period, it is probably more cost-effective over a patients' remaining lifetime, than if they had no surgery at all.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.